These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
146 related articles for article (PubMed ID: 27073579)
21. WNT pathway inhibitor pyrvinium pamoate inhibits the self-renewal and metastasis of breast cancer stem cells. Xu L; Zhang L; Hu C; Liang S; Fei X; Yan N; Zhang Y; Zhang F Int J Oncol; 2016 Mar; 48(3):1175-86. PubMed ID: 26781188 [TBL] [Abstract][Full Text] [Related]
22. COE inhibits vasculogenic mimicry in hepatocellular carcinoma via suppressing Notch1 signaling. Jue C; Min Z; Zhisheng Z; Lin C; Yayun Q; Xuanyi W; Feng J; Haibo W; Youyang S; Tadashi H; Shintaro I; Shiyu G; Yanqing L J Ethnopharmacol; 2017 Aug; 208():165-173. PubMed ID: 28694103 [TBL] [Abstract][Full Text] [Related]
23. Vasculogenic mimicry is associated with trastuzumab resistance of HER2-positive breast cancer. Hori A; Shimoda M; Naoi Y; Kagara N; Tanei T; Miyake T; Shimazu K; Kim SJ; Noguchi S Breast Cancer Res; 2019 Aug; 21(1):88. PubMed ID: 31387614 [TBL] [Abstract][Full Text] [Related]
24. Nodal signaling promotes vasculogenic mimicry formation in breast cancer via the Smad2/3 pathway. Gong W; Sun B; Zhao X; Zhang D; Sun J; Liu T; Gu Q; Dong X; Liu F; Wang Y; Lin X; Li Y Oncotarget; 2016 Oct; 7(43):70152-70167. PubMed ID: 27659524 [TBL] [Abstract][Full Text] [Related]
25. Aptamer-mediated impairment of EGFR-integrin αvβ3 complex inhibits vasculogenic mimicry and growth of triple-negative breast cancers. Camorani S; Crescenzi E; Gramanzini M; Fedele M; Zannetti A; Cerchia L Sci Rep; 2017 Apr; 7():46659. PubMed ID: 28425453 [TBL] [Abstract][Full Text] [Related]
26. Antimicrobial activity and metalloprotease inhibition of hinokitiol-related compounds, the constituents of Thujopsis dolabrata S. and Z. hondai MAK. Inamori Y; Shinohara S; Tsujibo H; Okabe T; Morita Y; Sakagami Y; Kumeda Y; Ishida N Biol Pharm Bull; 1999 Sep; 22(9):990-3. PubMed ID: 10513629 [TBL] [Abstract][Full Text] [Related]
27. Hinokitiol induces DNA demethylation via DNMT1 and UHRF1 inhibition in colon cancer cells. Seo JS; Choi YH; Moon JW; Kim HS; Park SH BMC Cell Biol; 2017 Feb; 18(1):14. PubMed ID: 28241740 [TBL] [Abstract][Full Text] [Related]
28. MMP-2 and MMP-13 affect vasculogenic mimicry formation in large cell lung cancer. Li Y; Sun B; Zhao X; Wang X; Zhang D; Gu Q; Liu T J Cell Mol Med; 2017 Dec; 21(12):3741-3751. PubMed ID: 28766880 [TBL] [Abstract][Full Text] [Related]
29. Antiproliferative Activity of Hinokitiol, a Tropolone Derivative, Is Mediated via the Inductions of p-JNK and p-PLCγ1 Signaling in PDGF-BB-Stimulated Vascular Smooth Muscle Cells. Yang PS; Wang MJ; Jayakumar T; Chou DS; Ko CY; Hsu MJ; Hsieh CY Molecules; 2015 May; 20(5):8198-212. PubMed ID: 25961161 [TBL] [Abstract][Full Text] [Related]
30. Lentivirus-mediated shRNA targeting Nanog inhibits cell proliferation and attenuates cancer stem cell activities in breast cancer. Hu C; Xu L; Liang S; Zhang Z; Zhang Y; Zhang F J Drug Target; 2016; 24(5):422-32. PubMed ID: 26339994 [TBL] [Abstract][Full Text] [Related]
31. Ovatodiolide Inhibits Breast Cancer Stem/Progenitor Cells through SMURF2-Mediated Downregulation of Hsp27. Lu KT; Wang BY; Chi WY; Chang-Chien J; Yang JJ; Lee HT; Tzeng YM; Chang WW Toxins (Basel); 2016 Apr; 8(5):. PubMed ID: 27136586 [TBL] [Abstract][Full Text] [Related]
32. Enhanced SLC34A2 in breast cancer stem cell-like cells induces chemotherapeutic resistance to doxorubicin via SLC34A2-Bmi1-ABCC5 signaling. Ge G; Zhou C; Ren Y; Tang X; Wang K; Zhang W; Niu L; Zhou Y; Yan Y; He J Tumour Biol; 2016 Apr; 37(4):5049-62. PubMed ID: 26546432 [TBL] [Abstract][Full Text] [Related]
33. Selective mode of action of plumbagin through BRCA1 deficient breast cancer stem cells. Somasundaram V; Hemalatha SK; Pal K; Sinha S; Nair AS; Mukhopadhyay D; Srinivas P BMC Cancer; 2016 May; 16():336. PubMed ID: 27229859 [TBL] [Abstract][Full Text] [Related]
34. Inhibitory effect of norcantharidin on melanoma tumor growth and vasculogenic mimicry by suppressing MMP-2 expression. Wang Z; You D; Lu M; He Y; Yan S Oncol Lett; 2017 Mar; 13(3):1660-1664. PubMed ID: 28454306 [TBL] [Abstract][Full Text] [Related]
35. cRGD-functionalized nanoparticles for combination therapy of anti-endothelium dependent vessels and anti-vasculogenic mimicry to inhibit the proliferation of ovarian cancer. Wang Y; Tong L; Wang J; Luo J; Tang J; Zhong L; Xiao Q; Niu W; Li J; Zhu J; Chen H; Li X; Wang Y Acta Biomater; 2019 Aug; 94():495-504. PubMed ID: 31252171 [TBL] [Abstract][Full Text] [Related]
36. An Overview of Vasculogenic Mimicry in Breast Cancer. Andonegui-Elguera MA; Alfaro-Mora Y; Cáceres-Gutiérrez R; Caro-Sánchez CHS; Herrera LA; Díaz-Chávez J Front Oncol; 2020; 10():220. PubMed ID: 32175277 [TBL] [Abstract][Full Text] [Related]
37. (-)-Epigallocatechin-3-gallate and hinokitiol reduce melanin synthesis via decreased MITF production. Kim DS; Park SH; Kwon SB; Li K; Youn SW; Park KC Arch Pharm Res; 2004 Mar; 27(3):334-9. PubMed ID: 15089040 [TBL] [Abstract][Full Text] [Related]
38. Downregulation of CXCR7 inhibits proliferative capacity and stem cell-like properties in breast cancer stem cells. Tang X; Li X; Li Z; Liu Y; Yao L; Song S; Yang H; Li C Tumour Biol; 2016 Oct; 37(10):13425-13433. PubMed ID: 27460092 [TBL] [Abstract][Full Text] [Related]
39. Dickkopf-1-promoted vasculogenic mimicry in non-small cell lung cancer is associated with EMT and development of a cancer stem-like cell phenotype. Yao L; Zhang D; Zhao X; Sun B; Liu Y; Gu Q; Zhang Y; Zhao X; Che N; Zheng Y; Liu F; Wang Y; Meng J J Cell Mol Med; 2016 Sep; 20(9):1673-85. PubMed ID: 27240974 [TBL] [Abstract][Full Text] [Related]
40. SIRT1, a Class III Histone Deacetylase, Regulates LPS-Induced Inflammation in Human Keratinocytes and Mediates the Anti-Inflammatory Effects of Hinokitiol. Lee JH; Moon JH; Lee YJ; Park SY J Invest Dermatol; 2017 Jun; 137(6):1257-1266. PubMed ID: 28257794 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]